In-vivo Bioequivalence Study of Azithromycin 500 mg Capsules of The Test Drug (ZITHROSAD 500 mg Cap., Sajjad Darou, Iran)
Not Applicable
Not yet recruiting
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Registration Number
- IRCT20200105046010N107
- Lead Sponsor
- Sajad darou shargh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index 18-28 kg/m^2
consent Age of 18-55 years old
Informed consent
Exclusion Criteria
Nicotine consumption
history Cardiovascular disease
History Liver and kidney
history Alcohol and opioid addiction
Allergy reactions history to Azithromycin
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of azithromycin's plasma concentration in healthy volunteers?
How does ZITHROSAD compare to ZITHROMAX in bioavailability and pharmacokinetics in Iranian populations?
Are there specific biomarkers that correlate with azithromycin efficacy in macrolide-sensitive individuals?
What adverse events are associated with azithromycin 500 mg capsules in clinical trials and how are they managed?
How do Sajjad Darou's azithromycin formulations compare to other generic macrolides in bioequivalence studies?